Correlation between autoantibodies and tumor markers in patients with lung cancer

doi:10.3877/cma.j.issn.1674-6902.2017.02.006

Abstract

Abstract:

Objective

The levels of autoantibodies (P53, PGP9.5, SOX2, GAGE7, GBU4-5 and MAGE) and tumor markers (CEA, SCC, CA125, NSE and CYFRA21-1) were studied in patients with lung cancer, to explore their correlation between autoantibodies and tumor markers in lung cancer.

Methods

To collected 112 cases of patients with lung cancer were recruited in Department of Respiratory Medicine Tang Du Hospital the Fourth Military Medical University from September 2016 to December 2016. The autoantibodies P53, PGP9.5, SOX2, GAGE7, GBU4-5 and MAGE were measured by Enzyme-linked immunosorbent assay (ELSA). And their CEA, SCC, CA125, NSE and CYFRA21-1 were measured by Electro-Chemiluminescence Immunoassay (ECLI). Then the relations between Autoantibodies and Tumor Markers were analyzed by spearman correlation test.

Results

By analyzing the levels of autoantibodies in patients with different pathological types of lung cancer, the median of GAGE7 is 7.30 U/ml in Lung adenocarcinoma patients, the result was significantly higher than squamous cell carcinoma, small cell carcinoma and other types of lung cancer patients(P=0.041). But P53, PGP9.5, SOX2, GBU4-5, MAGE and CAGE were no statistical difference. CEA and CA125 in lung adenocarcinoma, and SCC in lung squamous cell carcinoma were significantly increased(P<0.05). There were positive correlations between P53 and CEA and SCC (P=0.024, 0.016, respectively), between PGP9.5 and NSE (P<0.001), between GBU4-5 and SCC and CA199 (P<0.001, 0.011, respectively), between MAGE and SCC and CA199 (P=0.004, <0.001, respectively).

Conclusion

There was a positive correlation between autoantibodies and tumor markers. The both complement each other and more conducive to timely diagnosis of lung cancer.

Key words: Autoantibodies, Tumor markers, Bronchiogenic carcinoma

Hongjun Zhang, Yanfeng Fang, Wei Liu, Yonghong Xie, Faguang Jin, Xing Gu. Correlation between autoantibodies and tumor markers in patients with lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(02): 141-145.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2017.02.006

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2017/V10/I02/141

Figures/Tables 4

References 18

1	钱桂生. 肺癌不同病理类型发病率的变化情况及原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-6.
2	Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60(5): 277-300.
3	Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening[J]. CA Cancer J Clin, 2009, 59(1): 27-41.
4	Li Y, Karjalainen A, Koskinen H, et al. p53 autoantibodies predict subsequent development of cancer[J]. Int J Cancer, 2005, 114(1): 157-160.
5	Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure[J]. Thorax, 2008, 63(3): 228-233.
6	张卉，张树才. 肺癌筛查方法现状[J]. 中国肺癌杂志，2016, 19(10): 715-720.
7	李佳，齐军. 小细胞肺癌相关肿瘤标志物的研究进展[J]. 标记免疫分析与临床，2015, 22(12): 1293-1296.
8	卞春安，李忠佑，许有涛，等. 突变型P53蛋白在肺腺癌中的表达及其临床意义[J]. 中国肺癌杂志，2015, 18(1): 23-28.
9	高燕，吴雅清，许嵘. 非小细胞肺癌早期诊断生物标志物的研究[J]. 医学分子生物学杂志，2014, 11(4): 234-239.
10	张红军，顾兴，刘伟，等. 肿瘤标志物动态变化在肺癌疗效判断与随访中的意义[J/CD]. 中华肺部疾病杂志(电子版), 2016, 9(1): 26-30.
11	Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer[J]. Ann Oncol, 2011, 22(2): 383-389.
12	Chapman CJ, Healey GF, Murray A, et al. early CDT(R)-lung test: improved clinical utility through additional autoantibody assays[J]. Tumour Biol, 2012, 33(5): 1319-1326.
13	Jett JR, Peek LJ, Fredericks L, et al. Audit of the autoantibody test, early CDT(R)-lung, in 1 600 patients: an evaluation of its performance in routine clinical practice[J]. Lung Cancer, 2014, 83(1): 51-55.
14	Wilz SW, Liu D, Liu C, et al. Development of a test to identify bladder cancer in the urine of patients using mass spectroscopy and subcellular localization of the detected proteins[J]. Am J Transl Res, 2015, 7(8): 1458-1466.
15	王会中，任成山，金发光. 肿瘤生物标志物在肺癌患者检测中的临床意义及研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2016, 9(3): 329-333.
16	Yin L, Qu H, Chen Q. Proliferative response of peripheral blood mononuclear cells in anti-Hu antibody-associated patients with paraneoplastic neurological syndrome and their depressant effect on small cell lung cancer cells[J]. Mol Med Rep, 2015, 11(3): 1595-1600.
17	丁湘彧，张宝秋，张洁，等. 肺癌患者血清中肿瘤标志物检测的临床意义[J/CD]. 中华临床医师杂志(电子版), 2011, 5(16): 4646-4650.
18	支修益，姚舒洋. 肿瘤标志物在肺癌患者管理中的研究进展[J]. 首都医科大学学报，2015, 36(6): 986-991.

项　目		P53		PGP9.5		SOX2		GAGE7		GBU4-5		MAGE		CAGE
?		＋	－	＋	－	＋	－	＋	－	＋	－	＋	－	＋	－
年龄		?	?	?	?	?	?	?	?	?	?	?	?	?	?
?	≤60(n＝49)	8	41	0	49	2	47	4	45	5	44	5	44	6	43
?	>60(n＝63)	20	43	6	57	9	54	9	54	18	45	16	47	11	52
?	χ²/P值	3.495/0.062		?	?	3.240/0.072		1.007/0.316		5.698/0.017		4.176/0.041		0.582/0.445
性别		?	?	?	?	?	?	?	?	?	?	?	?	?	?
?	男(n＝74)	19	55	5	69	6	68	7	67	14	60	14	60	11	63
?	女(n＝38)	9	29	1	37	5	33	8	30	9	29	7	31	6	32
?	χ²/P值	0.053/0.818		0.843/0.359		0.723/0.395		2.909/0.088		0.349/0.554		0.004/0.949		0.017/0.897
病理类型		?	?	?	?	?	?	?	?	?	?	?	?	?	?
?	腺癌(n＝26)	6	20	0	26	3	23	8	18	3	23	1	25	5	21
?	鳞癌(n＝23)	7	16	2	21	0	23	1	22	6	17	6	17	4	19
?	小细胞癌	?	?	?	?	?	?	?	?	?	?	?	?	?	?
?	(n＝28)	7	21	1	27	3	25	1	27	3	25	6	22	3	25
?	未分类癌	?	?	?	?	?	?	?	?	?	?	?	?	?	?
?	(n＝28)	8	20	3	25	4	24	3	25	9	19	8	20	5	23
?	其它(n＝7)	0	7	0	7	1	6	0	7	2	5	0	7	0	7
?	χ²/P值	0.430/0.934		1.074/0.585		0.206/0.977		11.547/0.009		5.968/0.202		6.094/0.107		0.878/0.831

项　目		P53		PGP9.5		SOX2		GAGE7		GBU4-5		MAGE		CAGE
?		＋	－	＋	－	＋	－	＋	－	＋	－	＋	－	＋	－
年龄		?	?	?	?	?	?	?	?	?	?	?	?	?	?
?	≤60(n＝49)	8	41	0	49	2	47	4	45	5	44	5	44	6	43
?	>60(n＝63)	20	43	6	57	9	54	9	54	18	45	16	47	11	52
?	χ²/P值	3.495/0.062		?	?	3.240/0.072		1.007/0.316		5.698/0.017		4.176/0.041		0.582/0.445
性别		?	?	?	?	?	?	?	?	?	?	?	?	?	?
?	男(n＝74)	19	55	5	69	6	68	7	67	14	60	14	60	11	63
?	女(n＝38)	9	29	1	37	5	33	8	30	9	29	7	31	6	32
?	χ²/P值	0.053/0.818		0.843/0.359		0.723/0.395		2.909/0.088		0.349/0.554		0.004/0.949		0.017/0.897
病理类型		?	?	?	?	?	?	?	?	?	?	?	?	?	?
?	腺癌(n＝26)	6	20	0	26	3	23	8	18	3	23	1	25	5	21
?	鳞癌(n＝23)	7	16	2	21	0	23	1	22	6	17	6	17	4	19
?	小细胞癌	?	?	?	?	?	?	?	?	?	?	?	?	?	?
?	(n＝28)	7	21	1	27	3	25	1	27	3	25	6	22	3	25
?	未分类癌	?	?	?	?	?	?	?	?	?	?	?	?	?	?
?	(n＝28)	8	20	3	25	4	24	3	25	9	19	8	20	5	23
?	其它(n＝7)	0	7	0	7	1	6	0	7	2	5	0	7	0	7
?	χ²/P值	0.430/0.934		1.074/0.585		0.206/0.977		11.547/0.009		5.968/0.202		6.094/0.107		0.878/0.831

项　目		腺癌	鳞癌	小细胞癌	未分类癌	其它	Z值	P值
自身抗体		?	?	?	?	?	?	?
?	P53(U/ml)	3.60(2.15～12.15)	4.50(2.00～21.30)	2.80(1.80～19.70)	3.80(2.13～14.20)	4.90(2.10～9.30)	0.613	0.962
?	PGP9.5(U/ml)	3.65(2.08～4.20)	3.50(2.60～6.30)	3.00(1.80～3.85)	2.85(1.78～5.43)	3.40(1.70～7.80)	3.076	0.545
SOX2(U/ml)		1.25(0.58～3.08)	0.70(0.60～1.70)	0.90(0.35～3.25)	1.10(0.63～2.65)	2.30(1.30～8.00)	4.562	0.335
GAGE7(U/ml)		7.30(2.70～20.93)	3.00(2.00～4.80)	2.80(1.95～5.85)	3.85(2.70～9.15)	3.20(1.70～4.80)	9.969	0.041
GBU4～5(U/ml)		2.15(0.68～4.28)	1.70(0.90～8.40)	1.70(0.70～3.55)	2.75(1.30～33.08)	3.00(0.90～12.40)	3.023	0.554
MAGE(U/ml)		2.70(1.80～3.85)	2.00(1.60～15.90)	1.90(1.60～9.80)	4.30(1.73～12.58)	3.20(1.90～5.50)	2.012	0.734
CAGE(U/ml)		1.90(1.45～4.03)	1.70(1.30～2.80)	1.50(1.15～1.95)	2.00(1.53～4.08)	2.20(1.60～3.50)	3.989	0.407
肿瘤标志物		?	?	?	?	?	?	?
?	CEA(ng/ml)	12.17(3.44～68.34)	2.94(1.80～3.93)	3.07(1.63～13.29)	3.36(1.78～16.05)	2.12(1.29～6.44)	14.555	0.006
?	SCC(ng/ml)	0.42(0.29～0.56)	0.54(0.48～0.74)	0.43(0.41～0.46)	0.44(0.40～0.55)	0.45(0.37～0.50)	15.436	0.004
?	CA19～9(U/ml)	14.68(8.75～109.18)	11.42(9.18～14.58)	11.95(6.63～18.28)	14.28(8.23～59.51)	14.39(5.46～28.87)	2.674	0.614
?	CA125(U/ml)	54.68(27.41～194.93)	42.18(16.14～68.98)	28.69(19.66～38.53)	16.27(11.84～46.46)	23.11(11.54～27.68)	12.785	0.012
?	NSE(ng/ml)	14.05(11.23～17.76)	12.77(10.51～16.03)	14.93(12.12～29.60)	13.34(9.19～27.68)	13.74(9.70～15.27)	3.095	0.542
?	CYFRA21-1(ng/ml)	4.20(2.98～12.07)	4.83(2.48～8.60)	2.73(1.57～4.57)	3.36(1.91～5.56)	3.85(0.94～9.17)	5.723	0.221

项　目		腺癌	鳞癌	小细胞癌	未分类癌	其它	Z值	P值
自身抗体		?	?	?	?	?	?	?
?	P53(U/ml)	3.60(2.15～12.15)	4.50(2.00～21.30)	2.80(1.80～19.70)	3.80(2.13～14.20)	4.90(2.10～9.30)	0.613	0.962
?	PGP9.5(U/ml)	3.65(2.08～4.20)	3.50(2.60～6.30)	3.00(1.80～3.85)	2.85(1.78～5.43)	3.40(1.70～7.80)	3.076	0.545
SOX2(U/ml)		1.25(0.58～3.08)	0.70(0.60～1.70)	0.90(0.35～3.25)	1.10(0.63～2.65)	2.30(1.30～8.00)	4.562	0.335
GAGE7(U/ml)		7.30(2.70～20.93)	3.00(2.00～4.80)	2.80(1.95～5.85)	3.85(2.70～9.15)	3.20(1.70～4.80)	9.969	0.041
GBU4～5(U/ml)		2.15(0.68～4.28)	1.70(0.90～8.40)	1.70(0.70～3.55)	2.75(1.30～33.08)	3.00(0.90～12.40)	3.023	0.554
MAGE(U/ml)		2.70(1.80～3.85)	2.00(1.60～15.90)	1.90(1.60～9.80)	4.30(1.73～12.58)	3.20(1.90～5.50)	2.012	0.734
CAGE(U/ml)		1.90(1.45～4.03)	1.70(1.30～2.80)	1.50(1.15～1.95)	2.00(1.53～4.08)	2.20(1.60～3.50)	3.989	0.407
肿瘤标志物		?	?	?	?	?	?	?
?	CEA(ng/ml)	12.17(3.44～68.34)	2.94(1.80～3.93)	3.07(1.63～13.29)	3.36(1.78～16.05)	2.12(1.29～6.44)	14.555	0.006
?	SCC(ng/ml)	0.42(0.29～0.56)	0.54(0.48～0.74)	0.43(0.41～0.46)	0.44(0.40～0.55)	0.45(0.37～0.50)	15.436	0.004
?	CA19～9(U/ml)	14.68(8.75～109.18)	11.42(9.18～14.58)	11.95(6.63～18.28)	14.28(8.23～59.51)	14.39(5.46～28.87)	2.674	0.614
?	CA125(U/ml)	54.68(27.41～194.93)	42.18(16.14～68.98)	28.69(19.66～38.53)	16.27(11.84～46.46)	23.11(11.54～27.68)	12.785	0.012
?	NSE(ng/ml)	14.05(11.23～17.76)	12.77(10.51～16.03)	14.93(12.12～29.60)	13.34(9.19～27.68)	13.74(9.70～15.27)	3.095	0.542
?	CYFRA21-1(ng/ml)	4.20(2.98～12.07)	4.83(2.48～8.60)	2.73(1.57～4.57)	3.36(1.91～5.56)	3.85(0.94～9.17)	5.723	0.221

项　目	CEA		SCC		CA199		CA125		NSE		CYFRA21-1
项　目	r	P	r	P	r	P	r	P	r	P	r	P
P53	0.805	0.024	0.232	0.016	0.231	0.05	0.016	0.867	0.016	0.867	－0.05	0.606
PGP9.5	－0.044	0.643	0.073	0.452	－0.044	0.713	－0.013	0.893	0.364	<0.001	0.114	0.243
SOX2	0.036	0.71	0.128	0.185	－0.063	0.599	－0.053	0.587	0.107	0.268	－0.032	0.741
GAGE7	－0.015	0.877	0.137	0.157	－0.035	0.767	－0.075	0.44	－0.08	0.404	－0.06	0.536
GBU4-5	0.149	0.117	0.352	<0.001	0.3	0.011	－0.039	0.686	0.061	0.525	－0.017	0.861
MAGE	0.163	0.088	0.273	0.004	0.456	<0.001	－0.016	0.867	－0.073	0.449	－0.051	0.604
CAGE	－0.002	0.983	0.126	0.195	0.058	0.629	－0.045	0.644	0.109	0.255	－0.044	0.655

Please choose a citation manager

Content to export